Big Pharma Split Stock Probability of Future Stock Price Finishing Over 12.72

PRM Stock  CAD 13.12  0.01  0.08%   
Big Pharma's future price is the expected price of Big Pharma instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Big Pharma Split performance during a given time horizon utilizing its historical volatility. Check out Big Pharma Backtesting, Big Pharma Valuation, Big Pharma Correlation, Big Pharma Hype Analysis, Big Pharma Volatility, Big Pharma History as well as Big Pharma Performance.
  
At this time, Big Pharma's Price To Sales Ratio is very stable compared to the past year. As of the 29th of November 2024, Price Earnings To Growth Ratio is likely to grow to 0.94, though Price Earnings Ratio is likely to grow to (113.79). Please specify Big Pharma's target price for which you would like Big Pharma odds to be computed.

Big Pharma Target Price Odds to finish over 12.72

The tendency of Big Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to stay above C$ 12.72  in 90 days
 13.12 90 days 12.72 
about 99.0
Based on a normal probability distribution, the odds of Big Pharma to stay above C$ 12.72  in 90 days from now is about 99.0 (This Big Pharma Split probability density function shows the probability of Big Stock to fall within a particular range of prices over 90 days) . Probability of Big Pharma Split price to stay between C$ 12.72  and its current price of C$13.12 at the end of the 90-day period is nearly 4.85 .
Assuming the 90 days trading horizon Big Pharma Split has a beta of -0.0132 indicating as returns on the benchmark increase, returns on holding Big Pharma are expected to decrease at a much lower rate. During a bear market, however, Big Pharma Split is likely to outperform the market. Additionally Big Pharma Split has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Big Pharma Price Density   
       Price  

Predictive Modules for Big Pharma

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Big Pharma Split. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
12.1113.1214.13
Details
Intrinsic
Valuation
LowRealHigh
11.8115.2416.25
Details
Naive
Forecast
LowNextHigh
12.2013.2114.23
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
12.7113.5514.38
Details

Big Pharma Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Big Pharma is not an exception. The market had few large corrections towards the Big Pharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Big Pharma Split, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Big Pharma within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.15
β
Beta against Dow Jones-0.01
σ
Overall volatility
0.53
Ir
Information ratio -0.27

Big Pharma Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Big Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Big Pharma Split can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Big Pharma Split generated a negative expected return over the last 90 days
Big Pharma Split has a very high chance of going through financial distress in the upcoming years
The company reported the revenue of 311.76 K. Net Loss for the year was (645.35 K) with profit before overhead, payroll, taxes, and interest of 5.56 M.
Latest headline from news.google.com: Harvest Declares Big Pharma Split Corp. November 2024 Distribution - Yahoo Finance

Big Pharma Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Big Stock often depends not only on the future outlook of the current and potential Big Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Big Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding1.2 M
Cash And Short Term Investments204.2 K

Big Pharma Technical Analysis

Big Pharma's future price can be derived by breaking down and analyzing its technical indicators over time. Big Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Big Pharma Split. In general, you should focus on analyzing Big Stock price patterns and their correlations with different microeconomic environments and drivers.

Big Pharma Predictive Forecast Models

Big Pharma's time-series forecasting models is one of many Big Pharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Big Pharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Big Pharma Split

Checking the ongoing alerts about Big Pharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Big Pharma Split help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Big Pharma Split generated a negative expected return over the last 90 days
Big Pharma Split has a very high chance of going through financial distress in the upcoming years
The company reported the revenue of 311.76 K. Net Loss for the year was (645.35 K) with profit before overhead, payroll, taxes, and interest of 5.56 M.
Latest headline from news.google.com: Harvest Declares Big Pharma Split Corp. November 2024 Distribution - Yahoo Finance

Other Information on Investing in Big Stock

Big Pharma financial ratios help investors to determine whether Big Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Big with respect to the benefits of owning Big Pharma security.